Dyslipidemias: Pathology review

Last updated: November 01, 2022

Dyslipidemias: Pathology review

Year 1

Year 1

Skin histology
Introduction to pharmacology
Skin anatomy and physiology
Wound healing
Introduction to biostatistics
Types of data
Vaccinations
Inflammation
Nuclear structure
Pharmacodynamics: Agonist, partial agonist and antagonist
DNA structure
Anemia: Clinical
Anatomy of the heart
Hypertension
Hypertension: Clinical
Myocardial infarction
Clinical trials
Mitosis and meiosis
Calcium channel blockers
Class III antiarrhythmics: Potassium channel blockers
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug absorption and distribution
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Cardiac muscle histology
Blood histology
Artery and vein histology
Arteriole, venule and capillary histology
Loop diuretics
Thiazide and thiazide-like diuretics
Potassium sparing diuretics
Osmotic diuretics
Carbonic anhydrase inhibitors
Bone histology
Cartilage histology
Skeletal muscle histology
Central nervous system histology
Peripheral nervous system histology
Diabetes mellitus
Phenylketonuria (NORD)
Homocystinuria
Familial hypercholesterolemia
Fats and lipids
Cholesterol metabolism
Carbohydrates and sugars
Proteins
Extracellular matrix
Cytoskeleton and intracellular motility
Cell signaling pathways
Citric acid cycle
Electron transport chain and oxidative phosphorylation
Amino acid metabolism
Nitrogen and urea cycle
Nucleotide metabolism
Introduction to biostatistics
Types of data
Probability
Mean, median, and mode
Range, variance, and standard deviation
Standard error of the mean (Central limit theorem)
Normal distribution and z-scores
Type I and type II errors
Study designs
Ecologic study
Cross sectional study
Case-control study
Cohort study
Randomized control trial
Sensitivity and specificity
Positive and negative predictive value
Test precision and accuracy
Atrophy, aplasia, and hypoplasia
Hyperplasia and hypertrophy
Metaplasia and dysplasia
Bone tumors
Osteomyelitis
Osteoporosis
Osteomalacia and rickets
Septic arthritis
Cauda equina syndrome
The Oral Microbiota and Systemic Health
Bacterial structure and functions
Nasal cavity and larynx histology
Trachea and bronchi histology
Bronchioles and alveoli histology
Inheritance patterns
Mendelian genetics and punnett squares
Hardy-Weinberg equilibrium
DNA mutations
Neuromuscular junction and motor unit
Pharmacodynamics: Drug-receptor interactions
Cholinergic receptors
Adrenergic receptors
Blood products and transfusion: Clinical
Muscle contraction
Sliding filament model of muscle contraction
Nervous system anatomy and physiology
Parasympathetic nervous system
Slow twitch and fast twitch muscle fibers
Enteric nervous system
Sympathetic nervous system
Resting membrane potential
Neuron action potential
Cell membrane
Selective permeability of the cell membrane
Blood groups and transfusions
Blood components
Oxygen binding capacity and oxygen content
Oxygen-hemoglobin dissociation curve
Body fluid compartments
Movement of water between body compartments
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Clot retraction and fibrinolysis
Carbon dioxide transport in blood
Bones of the vertebral column
Bones of the vertebral column
Joints of the vertebral column
Joints of the vertebral column
Joints of the wrist and hand
Bones of the upper limb
Fascia, vessels and nerves of the upper limb
Anatomy of the brachial plexus
Anatomy of the arm
Muscles of the forearm
Vessels and nerves of the forearm
Muscles of the hand
Anatomy of the sternoclavicular and acromioclavicular joints
Anatomy of the glenohumeral joint
Anatomy of the elbow joint
Anatomy of the radioulnar joints
Paired t-test
Two-sample t-test
Hypothesis testing: One-tailed and two-tailed tests
Methods of regression analysis
Spearman's rank correlation coefficient
Mann-Whitney U test
Chi-squared test
Kaplan-Meier survival analysis
Incidence and prevalence
Relative and absolute risk
Odds ratio
Attributable risk (AR)
Direct standardization
Indirect standardization
Disease causality
Selection bias
Information bias
Confounding
Innate immune system
Complement system
T-cell activation
B-cell activation, differentiation, and contraction
Cell-mediated immunity of natural killer and CD8 cells
Antibody classes
Upper respiratory tract infection
Heart failure
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Dyslipidemias: Pathology review
Atherosclerosis and arteriosclerosis: Pathology review
Familial hypercholesterolemia
Deep vein thrombosis and pulmonary embolism: Pathology review
Chronic venous insufficiency
Ischemia
ECG cardiac infarction and ischemia
Angina pectoris
Aneurysms
Asthma: Clinical
Chronic bronchitis
Emphysema
Pulmonary hypertension
Idiopathic pulmonary fibrosis
Bronchiectasis
Lung cancer
Chronic obstructive pulmonary disease (COPD): Clinical
Respiratory distress syndrome: Pathology review
Myocardial infarction
Vasculitis
ACE inhibitors, ARBs and direct renin inhibitors
Adrenergic receptors
Adrenergic antagonists: Alpha blockers
Class II antiarrhythmics: Beta blockers
Adrenergic antagonists: Beta blockers
Antiplatelet medications
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Arteriole, venule and capillary histology
Microcirculation and Starling forces
Blood pressure, blood flow, and resistance
Resistance to blood flow
Lymphatic system anatomy and physiology
Laminar flow and Reynolds number
Compliance of blood vessels
Pressures in the cardiovascular system
Physiological changes during exercise
Measuring cardiac output (Fick principle)
Stroke volume, ejection fraction, and cardiac output
Frank-Starling relationship
Pressure-volume loops
Changes in pressure-volume loops
Cardiac work
Cardiac preload
Cardiac afterload
Law of Laplace
Baroreceptors
Renin-angiotensin-aldosterone system
Chemoreceptors
Cardiac conduction system
Action potentials in pacemaker cells
Action potentials in myocytes
Cardiac excitation-contraction coupling
Cardiac contractility
ECG basics
Cerebral circulation
Coronary circulation
Respiratory system anatomy and physiology
Reading a chest X-ray
Lung volumes and capacities
Anatomic and physiologic dead space
Alveolar surface tension and surfactant
Ventilation
Regulation of pulmonary blood flow
Zones of pulmonary blood flow
Pulmonary shunts
Ventilation-perfusion ratios and V/Q mismatch
Airflow, pressure, and resistance
Diffusion-limited and perfusion-limited gas exchange
Gas exchange in the lungs, blood and tissues
Oxygen binding capacity and oxygen content
Oxygen-hemoglobin dissociation curve
Carbon dioxide transport in blood
Carpal tunnel syndrome

Questions

USMLE® Step 1 style questions USMLE

0 of 6 complete

Start
An 8-month-old Caucasian infant is brought to the pediatrics PA’s office by his parents for evaluation of failure to thrive and persistent frothy stools. He was born at term with no antenatal or delivery problems. His parents and older brother are all healthy. The patient is below the 10th percentile for both height and weight. Physical examination reveals that the patient has difficulty with balance and poor muscle coordination. In addition, the patient is found to have normal central vision but impaired peripheral vision. A peripheral smear is obtained and reveals abnormal red blood cells with a spiked membrane, as depicted below:  


  Reproduced from: Wikimedia Commons  

Which of the following compounds is most likely deficient given this patient’s clinical presentation?  
  

Transcript

Watch video only

Jamie is a 24-year-old male presenting to the emergency department complaining of sudden onset chest pain and shortness of breath when playing soccer.

On further evaluation, his ECG showed ST-segment elevation and laboratory evaluation showed elevated troponin I levels.

After instituting treatment, Jamie and his family inquire about the odd early onset of his disease.

The physical examination of the skin showed numerous xanthomas.

A lipid panel is ordered and shows marked elevation of LDL.

Jamie had a myocardial infarction which was caused by an underlying lipid disorder.

Lipid disorders include both hyper and hypolipidemia.

Hyperlipidemia can manifest as a high level of cholesterol, a high level of triglycerides, or a combination of both.

Hypolipidemia is the opposite where there’s a low level of these lipids.

So let’s do a quick overview of the physiology of lipid metabolism.

After eating a fatty meal, cholesterol and fatty acids enter the intestinal cells.

The fatty acids are assembled into triglycerides, and then they, along with a small amount of cholesterol, are packaged together with lipoproteins to form chylomicrons.

Chylomicrons move into the lymphatic vessels and eventually end up getting emptied into the left and right subclavian veins where they enter into the blood.

Now an enzyme in capillaries called lipoprotein lipase breaks down the chylomicrons to free the triglycerides, and then it also breaks the triglycerides down into fatty acids.

These can be taken up by nearby tissues to generate energy, like in the muscle cells, or for storage, like in adipocytes.

The remains of the chylomicrons will contain lipoproteins and a small amount of triglyceride and cholesterol, so these chylomicron remnants head to the liver to deposit the leftover lipid molecules.

The Liver is also synthesizing fatty acids and cholesterol and it will combine these with the ones from the chylomicron remnants and package them together.

But instead of chylomicrons, they are packaged into very low density lipoproteins, or VLDLs.

Compared to chylomicrons, these are made of different lipoproteins and contain a bit more cholesterol.

VLDLs are released from the liver and enter into the blood where lipoprotein lipase in the capillaries break them down again to release triglycerides for nearby tissue to use.

As more and more triglycerides leave the VLDL, it becomes an IDL or intermediate density lipoprotein, and when there’s more cholesterol left than triglyceride, it becomes an LDL.

LDLs then travel around in the blood, where they are endocytosed by cells with LDL receptors.

This can happen when they go back to the liver, or in peripheral tissues that need cholesterol to function.

Alright, the causes of hyperlipidemia can be broadly classified into primary hyperlipidemias, which are the familial, inherited hyperlipidemias, and secondary, or acquired hyperlipidemias, which are caused by various other diseases and medications.

Depending on the type and severity, hyperlipidemia can result in various clinical manifestations, or it can be completely asymptomatic.

Beginning from the outside, skin manifestations include xanthomas, which are deposits of fat under the skin and in the tendons.

These occur when extremely high levels of lipoproteins or triglycerides in the blood leak out of the blood vessels.

When these deposits occur around the eyelid, it gets a special name; xanthelasma.

Speaking of the eyes, lipids can deposit around the cornea, creating a brown ring of fat called a corneal arcus. Lipid deposition in the liver can cause fatty liver disease, also called hepatic steatosis.

Now, the most worrisome complication of hyperlipidemias is atherosclerotic cardiovascular disease, including coronary artery disease, stroke, peripheral vascular disease and carotid artery stenosis.

Okay, so let’s look at the primary, or Familial hyperlipidemias, which are inherited in either an autosomal dominant or recessive manner.

Although there are many, the most high yield ones often tested on exams are types 1 through 4.

Type 1 hyperlipidemia is an autosomal recessive disorder characterized by elevation of chylomicrons in the blood, so it’s also referred to as hyperchylomicronemia.

This occurs secondary to a deficiency in lipoprotein lipase.

This enzyme also normally requires a cofactor called apolipoprotein C2, so deficiency of this cofactor can also lead to type 1 hyperlipidemia.

This condition is characterized by the rapid development of many xanthomas on the back and buttocks that can be itchy.

Due to the rapid nature of their development, they’re referred to as eruptive xanthomas.

In addition, the high concentration of triglycerides in chylomicrons can often lead to the development of acute pancreatitis.

This occurs because when the pancreatic cells encounter triglycerides, they release the enzyme lipase, which breaks them down into free fatty acids.

Too many free fatty acids can be toxic to the pancreatic cells, leading to acute pancreatitis.

Another unique feature of type 1 hyperlipidemia is that atherosclerotic cardiovascular disease is not a complication.

That’s because the development of an atherosclerotic plaque is usually related to the elevation of other lipoproteins like low-density lipoprotein, or LDL, and not related to the elevation of chylomicrons.

Finally, people with this condition can develop hepatosplenomegaly.

An important clue that might appear on your exams is that when fasting serum is chilled, the chylomicrons will form a creamy layer at the top of the test tube.

Alright, type 2 familial hyperlipidemia is an autosomal dominant condition also known as familial hypercholesterolemia.

It’s characterized by the elevation of LDL cholesterol if it’s type “A,” and both LDL and VLDL if it’s type B.

Okay, so normally, the liver can decrease cholesterol levels by recycling LDL in the blood.

LDL attaches to its own LDL receptor on the surface of liver cells, and with the help of a protein called apolipoprotein B-100, or ApoB-100, it enters the liver cells.

So in this condition, either the LDL receptor or ApoB-100 are absent or defective, causing LDL levels go up.

Because the liver cells aren’t getting any LDL back, they begin to “think” that cholesterol is actually low in the blood, and so they start making even more cholesterol, and sending them out in VLDL.

As you can imagine, this would worsen the problem.

Unlike type 1, type 2 hyperlipidemia will increase the risk of developing atherosclerosis, and this is high yield.

In fact, individuals may present with coronary artery disease as early as 20 years old!

Sources

  1. "Fundamentals of Pathology" H.A. Sattar (2017)
  2. "Hyperlipidemia: diagnostic and therapeutic perspectives" J Clin Endocrinol Metab (2000)
  3. "Lecture Notes: Cardiology" Wiley-Blackwell (2008)
  4. "Pathophysiology of Heart Disease" Wolters Kluwer Health (2015)
  5. "Familial hypobetalipoproteinemia: genetics and metabolism" Cell Mol Life Sci. (2005)